Login
Definium Therapeutics, Inc. logo

Definium Therapeutics, Inc.

definiumtx.com

What Do They Do?

Develops potential medicines for adults with generalized anxiety disorder, major depressive disorder and autism spectrum disorder.

How Do They Make Money?

No revenue reported yet.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ +24% (Loss)
vs −$67.3M in Q3 FY2025

Treatment scope The older report described development for generalized anxiety disorder and attention deficit hyperactivity disorder; the latest report describes development for generalized anxiety disorder and major depressive disorder.

Who Do They Compete With?

Competes with AtaiBeckley, Compass, GH Research, Helus, Otsuka, Johnson & Johnson, Intra-Cellular, Axsome, Resilient, Nova Mentis Life Science, Mycrodose Therapeutics, Novartis, Roche, Pfizer, Biogen, Jazz Pharmaceuticals, Supernus Pharmaceuticals, AbbVie, Neumora Therapeutics, and Praxis Precision Medicines

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support